Ripasudil hydrochloride dihydrate
![]() |
- ₹0
- Product name: Ripasudil hydrochloride dihydrate
- CAS: 887375-67-9
- MF: C15H21ClFN3O3S
- MW: 377.86
- EINECS:
- MDL Number:MFCD26960897
- Synonyms:K-115 HCL;Ripasudil free base;RipasudilHCl Hydrate;K115 HCl Dihydrate;RIPASUDIL HYDROCHLORIDE HYDRATE;(2S)-1-[(4-Fluoro-5-isoquinolinyl)sulfonyl]hexahydro-2-methyl-1H-1,4-diazepine monohydrochloride dihydrate;K-115 (HCl H2O);Ripasudil HCl Dihydrate
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
storage temp. :Store at -20°C
solubility :insoluble in EtOH; ≥123.2 mg/mL in DMSO; ≥41.7 mg/mL in H2O
form :solid
color :White to off-white
Stability :Hygroscopic
solubility :insoluble in EtOH; ≥123.2 mg/mL in DMSO; ≥41.7 mg/mL in H2O
form :solid
color :White to off-white
Stability :Hygroscopic
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|
Description
Ripasudil hydrochloride hydrate (Glanatec®) was approved in Japan in 2014 for the treatment of glaucoma and ocular hypertension. Originally discovered by D. Western Therapeutics Institute, Inc. and licensed by the Kowa Company, Ltd, ripasudil functions as a selective Rho-kinase inhibitor and reduces intraocular pressure by stimulation of aqueous humour drainage of the trabecular meshwork. While this recent approval allows for use of ripasudil as a twice-daily monotherapy treatment when other drugs cannot be used or are not effective, clinical trials using ripasudil as a combination therapy with other glaucoma drugs have shown promising results in the treatment of primary open-angle glaucoma or ocular hypertension. Currently, the Kowa Company is also pursuing trials focused on the use of ripasudil for the treatment of diabetic retinopathy and diabetic macular edema.More related product prices
k115 free base Riociguat 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrile